Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 12/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | PIK3CD | O00329 | 3/20 | 0.39 |
| ▸ | TRPA1 | O75762 | 2/20 | 0.36 |
| ▸ | HTR1A | P08908 | 2/20 | 0.36 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.36 |
| ▸ | ABL1 | P00519 | 1/20 | 0.35 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL389133 | 0.84 | GPR119 (0.66) | GPR119CYP2C9 | |
| SCHEMBL5140735 | 0.81 | CYP2C9 (0.44) | GPR119CYP2C9ABL1 | |
| Pyridine SCHEMBL27769077 | 0.78 | GPR119 (0.44) | GPR119CYP2C9HTR1ASLC6A2SLC6A4 | |
| SCHEMBL390220 | 0.77 | GPR119 (0.66) | GPR119CYP2C9 | |
| SCHEMBL6066167 | 0.76 | GPR119 (0.46) | GPR119CYP2C9TRPA1HTR1ASLC6A2 | |
| SCHEMBL1890890 | 0.75 | GPR119 (0.66) | GPR119CYP2C9 | |
| SCHEMBL6066219 | 0.74 | GPR119 (0.48) | GPR119CYP2C9TRPA1HTR1ASLC6A2 | |
| Hydrochloric Acid SCHEMBL1895317 | 0.74 | GPR119 (0.65) | GPR119CYP2C9 | |
| SCHEMBL27734766 | 0.74 | GPR119 (0.55) | GPR119CYP2C9TRPA1HTR1ASLC6A2 | |
| SCHEMBL5051085 | 0.73 | SLC6A2 (0.61) | GPR119HTR1ASLC6A2SLC6A4SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2004157-A2 | USE OF GPR119 RECEPTOR AGONISTS FOR INCREASING BONE MASS AND FOR TREATING OSTEOPOROSIS, AS WELL AS COMBINATION THERAPY RELATING THERETO | Arena Pharmaceuticals, Inc. (US) | 2008-12-24 | — | — | EP | disclosed |
| WO-2007120702-A2 | USE OF GPR119 RECEPTOR AGONISTS FOR INCREASING BONE MASS AND FOR TREATING OSTEOPOROSIS, AND COMBINATION THERAPY RELATING THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2007-10-25 | — | — | WO | disclosed |